Publique un comentario 
Aspectos farmacológicos y reacciones adversas a nivel gástrico y hepático de inhibidores de la bomba de protones
Resumen
Introducción: Los inhibidores de bomba de protones (IBP) son los supresores de la secreción gástrica más efectivos, por lo que se encuentran entre los fármacos de primera elección en patologías que cursan con aumento de la secreción ácida gástrica. En los últimos años, diversos estudios básicos, clínicos y epidemiológicos han alertado sobre posibles eventos adversos potencialmente graves relacionados con la administración continuada y a largo plazo de este grupo de medicamentos. Objetivo: Describir las principales reacciones adversas asociadas al consumo prolongado de inhibidores de la bomba de protones. Métodos: Se realiza una descripción de sus principales características y se describen las reacciones adversas a largo plazo a nivel gástrico y en pacientes con cirrosis hepática (CH) a partir de la revisión de la bibliografía disponible. Conclusiones: La asociación del uso de IBP con la aparición de efectos adversos puede conllevar una morbimortalidad no despreciable, su prescripción inadecuada es un problema común y afecta a todos los niveles asistenciales.
Palabras claves: Inhibidores de la Bomba de Protones, reacciones adversas
Palabras clave
Referencias
Arnold J., Bruning K, Riquelme A y Vargas JI. Eventos adversos asociados al uso de inhibidores de bomba de protones: un análisis crítico de la evidencia actual. Gastroenterol. latinoam 2018;29(2): 61-8
de la Coba C, Arguelles Arias F, Martín de Argila C, Júdez J, Linares A, Ortega Alonso A, Rodríguez E, Rodríguez Téllez M, Vera I, et al. Efectos adversos de los inhibidores de la bomba de protones: revisión de evidencias y posicionamiento de la Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig. [Internet] 2016 [citado 2018 Nov 16];108(4):207-24. Disponible en: http://scielo.isciii.es/pdf/diges/v108n4/es_especial.pdf
Oscanoa E. Teodoro. Seguridad de los Inhibidores de la Bomba de Protones. Rev Gastroenterol. [Internet] 2011; 31: 49-55 [Consultado: 08/12/2016]. Disponible en: http://perurevista.com/index.php/gastro/article/view/2314/1911
Cardona Ospina JA, Medina Morales DA, Rodríguez Morales AJ, Machado Alba JE. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. [Revisión de Tema]. [Internet] 2016 [citado 2018 Nov 16]. Disponible en: http://www.scielo.org.co/pdf/rcg/v31n4/v31n4a10.pdf
Aguilera Castro L, Martín de Argila de Prados M, Albillos Martínez A. Consideraciones prácticas en el manejo de los inhibidores de la bomba de protones. [Revisión] Rev Esp Enferm Dig. [Internet] 2016 [citado 2018 Nov 16]. Disponible en: http://scielo.isciii.es/pdf/diges/v108n3/es_revision.pdf
Simo Minana J. Use of prescription drugs in Spain and Europe. Aten Primaria. 2012;44:335-47.
Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005;21:1203-9. DOI: 10.1111/j.1365-2036.2005.02454.x
Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561-8. DOI: 10.2169/internalmedicine.49.4064
Álvarez-Castello R. Inhibidores de la bomba de protones. Rev Hosp Jua Mex 2018; 85(3): 124-126
Avinash K. Nehra, Jeffrey A. Alexander, Conor G. Loftus, and Vandana Nehra. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. (internet) February 2018 (citec 2 Jam 2019;93(2):240-246. Available from: https://doi.org/10.1016/j.mayocp.2017.10.022www.mayoclinicproceedings.org
Martin-Echevarria E, Pereira Julia A, Torralba M, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev EspEnferm Dig 2008;100:76-81.
Batuwitage BT, Kingham JGC, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8. DOI: 10.1136/pgmj.2006.05115
Urquizo Ayala G, Arteaga Coarite R. Uso de Inhibidores de la Bomba de Protones en la práctica clínica:¿terapia adecuada para todos?. Rev Med La Paz Enero - Junio 2018;24(1):70-7
Esplugues JV. A pharmacological approach to gastric acid inhibition. Drugs 2005;65(Suppl1):7-12. DOI: 10.2165/00003495-20056500100003
Gomollon F, Calvet X. Optimizing acid inhibition treatment. Drugs 2005;65(Suppl1):25-33. DOI: 10.2165/00003495-200565001-00004
Sjostrom JE, Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: Effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol 1996;44:425-33. DOI: 10.1099/00222615-44-6-425
Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: What the practicing physician needs to know. Drugs 2003;63:2739-54. DOI: 10.2165/00003495-200363240-00004
Flores Jesus, Antonio Armijo Simón, Mediavilla Martínez África. Farmacología humana. 6º edición. Editorial Elsevier; 2013
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. Editorial Office of Gut and Liver; 2017 Jan 15; 11(1):27–37.
Martín de Argila C. Safety of potent gastric acid inhibition. Drugs 2005;65(Suppl1):97-104. DOI: 10.2165/00003495-200565001-00013
Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018 Feb;93(2):240–6.
Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med. BioMed Central; 2016 Nov 9;14(1):172.
Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl3):27-36. DOI: 10.1046/j.13652036.1999.00022.x
Arroyo Villarino M, Lanas Arbeloa A. Gastroenteropatía por AINE. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011.p. 123-31.
Calvet X, Gomollon F. What is potent acid inhibition, and how can it be achieved? Drugs 2005;65(Suppl1):13-23. DOI: 10.2165/00003495200565001-00004
Baldwin CM, Keam SJ. Rabeprazole: A review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373401. DOI: 10.2165/00003495-200969100-00007
Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009;15:990-5. DOI:10.3748/wjg.15.990
Pérez Gisbert J, Martín Argila C. Úlcera péptica e infección por Helicobacter pylori. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011.p. 109-21.
Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers - a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-62. DOI: 10.1001/jamainternmed.2014.4056
Yen H-H, Yang C-W, Su W-W, et al. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012;12:66. DOI: 10.1186/1471-230X-12-66
Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:1066-78.
Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:13-22.e1. DOI: 10.1016/j.cgh.2015.07.041
Molina-Infante J, Bredenoord AJ, Cheng E, Dellon ES, Furuta GT, Gupta SK, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut [Internet] 2016 [cited 22 Jan 2019];524-31 available from: http://www.ncbi.nlm.nih.gov/pubmed/26685124 DOI: 10.1136/gutjnl-2015-310991
Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 2006;55:1056-7. DOI: 10.1136/gut.2006.094912
Yu L-Y, Sun L-N, Zhang X-H, Li Y-Q, Yu L, Yuan Z-Q-Y, et al. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Adv Ther. Springer Health care; 2017 Apr 20;34(5):1070–86.
Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010; 139(4):1115-27.
Sebastián Domingo jj. Inhibidores de la bomba de protones y carcinogénesis gástrica. Med Clin (Barc) 2017; No. Of pages 2 Available from: https://doi.org/10.1016/j.medcli.2018.03.028
Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. ClinGastroenterolHepatol2016;14:1706-19.
Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, et al. Proton pump inhibitors cohort and risk of gastric cancer: A population-based study. Br J Cancer. 2009;100:1503–7.
García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk osoesophageal and gastric adenocarcinoma: A nested case control study in the UK. Gut. 2006;55:1538-44
Brusselaers N, Wahlin K, Engstrand L, Lagergren proton J. Maintenance therapy with pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015;42:649-63.
Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med 2013;16:449-58.
Cheung KS, Chan EW, Wong AYS, ton Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. Gut. 2018;67:28–35.
Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301(20):2120-8. DOI: 10.1001/jama.2009.722
Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection. ArchInternMed 2010;170(9):772-8. DOI:10.1001/archinternmed.2010.73
Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann R, Sanyal AJ, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-4. DOI:10.1038/ajg.2009.80
Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res 2015;14:7490-501. DOI:10.4238/2015.July.3.25
Goel GA, Deshpande A, Lopez R, Hall GS, Duin DV and Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012;10:422-7. DOI:10.1016/j.cgh.2011.11.019
Deshpande A, Pasupuleti V, Thota P, Pant Ch, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. J Gastroenterol Hepatol 2013;28:235-42. doi: 10.1111/jgh.12065
Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol 2014;28(6):330-4. DOI:10.1155/2014/751921
Min YW, Lim KS, Min BH, Min BH, Gwak GY, Paik YH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther 2014;40:695-704. DOI: 10.1111/apt.12875
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One 2014;9(11): e110503. DOI:10.1371/journal.pone.0110503
O’Leary JG., Rajender Reddy K, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. ClinGastroenterolHepatol [internet] 2015 [cited 22 Jan 2019];13:753-9. e1-2. Available from: http://dx.doi.org/10.1016/].ogh.2014.07.060
Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. J Hepatol 2015;62:1056-60. DOI:10.1016/j.jhep.2014.11.036
Chang SS, Lai CC, Lee MT Gabriel, Lee YC, Tsai YW, Hsu WT, and Lee CC. Risk of spontaneous bacterial peritonitis associated with gastric Acid suppression. Medicine 2015;94(22):1-7. DOI: 10.1097/MD.0000000000000944
Miura K, Tanaka A, Yamamoto T, Adachi M and Takikawa H. Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Intern Med 2014;53:1037-42. DOI: 10.2169/internalmedicine.53.2021
Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. Journal of Gastroenterology and Hepatology. Wiley/Blackwell (10.1111); 2013 Jan 22;28(2):235–42.
Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 2015;35:362-9. DOI: 10.1111/liv.12593
Van Vlerken LG, Huisman EJ, van Hoek B, Renooij Wde Rooij FWM, Siersema PD and van Erpecum KJ. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation 2012;42:760-7. DOI:10.1111/j.1365-2362.2011.02643.x
Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 2015;41:459-66. DOI: 10.1111/apt.13061
Enlaces refback
- No hay ningún enlace refback.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.